

BIAL Pharma UK Ltd

BIAL Pharma UK Ltd was established in the UK in May 2016. The company is a wholly owned subsidiary of Bial Portela & C^a., S.A; a Portugal Headquartered Pharmaceutical company.

This disclosure submission relates solely to the UK operation of BIAL Pharma UK Ltd.

UK healthcare professionals, who have received transfer of value, whether engaged with BIAL Pharma UK Ltd, our parent company Bial Portela & C^a., S.A, or any other Bial owned affiliate, will be captured in this disclosure submission.

BIAL Pharma UK Ltd has not considered any transfer of value that may have occurred between non-UK healthcare professionals and BIAL Portela & C^a., S.A., or any of its affiliates, in other markets outside of the UK.

With regards to the specific categories for disclosing transfer of value, we confirm that all 2019 sponsorship, fees and relevant transfer of value is in-line with our current UK SOPs.

We make further comment as below;

HCP / HCO Transfer of Value

All individuals disclosed in this submission, have provided their authorisation to share their transfer of value, by signing the relevant formal contract between BIAL Pharma UK Ltd and the relevant UK healthcare professional.

Where a HCP has expressly requested that their name is not disclosed, BIAL Pharma UK Ltd have respected that decision, and consolidated those amounts into an aggregated transfer of value, indicating the No of HCPs captured in this manner.

Healthcare Professionals workplace addresses have come from our inhouse CRM database, which is provided & maintained by IQVIA, using their OneKey healthcare industry database

(<https://www.onekeydata.com/onekey/overview>)

Research and Development

BIAL Pharma UK Ltd have captured the total value of 2019 Research and Development spend, in the indicated section of the disclosure template. The transfer of value for R&D will include BIAL commissioned research held in the UK.

Any transfer of value cost associated with Investigator Initiated Studies, supported by BIAL Pharma UK Ltd, have been captured under the requesting HCO.

Finance

VAT:

No healthcare professionals contracted or receiving transfer of value in this period have indicated they are VAT registered, therefore in this submission VAT has not been applied.

Tax:

All healthcare professionals have received indicated transfer of value, with the understanding those healthcare professionals will manage any due taxation themselves

Exchange Rates:

If transfer of value was received in Euros, this has been converted to £ Sterling using the prevailing rate at the time of payment. No other applicable financial considerations needed to be addressed in this submission.

Jason Stone,

Country Manager

Bial Pharma UK Ltd

24th July 2020